This approval represents a significant regulatory milestone, making Proliv™Rx the first and only at-home neuromodulation ...

After greenlighting 56 novel therapeutics in 2025, four notable applications continue to await the agency’s action after ...

Dyslexia is a common developmental disorder, affecting around 7% of the global population. It is characterized by ...

A massive gene experiment exposed how the brain builds itself, and uncovered a hidden cause of severe developmental issues.